X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1530) 1530
Book Review (488) 488
Publication (130) 130
Book Chapter (14) 14
Conference Proceeding (13) 13
Newspaper Article (4) 4
Magazine Article (2) 2
Dissertation (1) 1
Presentation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (1085) 1085
humans (937) 937
trastuzumab (914) 914
oncology (814) 814
breast cancer (767) 767
female (663) 663
breast neoplasms - drug therapy (477) 477
cancer (468) 468
trastuzumab emtansine (443) 443
chemotherapy (416) 416
her2 (328) 328
metastasis (321) 321
receptor, erbb-2 - metabolism (302) 302
breast neoplasms - pathology (300) 300
animals (279) 279
open-label (269) 269
antineoplastic agents - therapeutic use (264) 264
care and treatment (246) 246
pertuzumab (246) 246
maytansine - analogs & derivatives (244) 244
therapy (237) 237
erbb-2 protein (233) 233
middle aged (233) 233
pharmacology & pharmacy (222) 222
epidermal growth factor (221) 221
lapatinib (219) 219
skin and connective tissue diseases (211) 211
cancer therapies (207) 207
tumors (199) 199
aged (193) 193
medicine & public health (190) 190
monoclonal-antibody (190) 190
survival (188) 188
adult (185) 185
analysis (183) 183
breast neoplasms - metabolism (183) 183
antibodies, monoclonal, humanized - therapeutic use (175) 175
breast-cancer (171) 171
treatment outcome (166) 166
receptor, erbb-2 - antagonists & inhibitors (164) 164
research (162) 162
drug therapy (157) 157
phase-ii (157) 157
clinical trials (156) 156
patients (154) 154
receptor, erbb-2 - genetics (152) 152
metastatic breast-cancer (151) 151
antineoplastic combined chemotherapy protocols - therapeutic use (146) 146
cell line, tumor (142) 142
breast neoplasms - genetics (139) 139
health aspects (135) 135
metastases (133) 133
antineoplastic agents (132) 132
t-dm1 (130) 130
maytansine - therapeutic use (122) 122
monoclonal antibodies (122) 122
antimitotic agents (121) 121
neoplasms (121) 121
antibody-drug conjugate (119) 119
antineoplastic agents - pharmacology (119) 119
molecular targeted therapy (119) 119
docetaxel (117) 117
growth-factor receptor (116) 116
trastuzumab - therapeutic use (116) 116
antibodies, monoclonal, humanized - administration & dosage (114) 114
disease-free survival (114) 114
mice (114) 114
metastatic breast cancer (113) 113
adjuvant chemotherapy (112) 112
double-blind (110) 110
combination (107) 107
cytotoxicity (107) 107
prognosis (107) 107
resistance (107) 107
antibodies (106) 106
review (106) 106
phase-ii trial (105) 105
efficacy (103) 103
1st-line treatment (101) 101
hematology, oncology and palliative medicine (101) 101
trastuzumab emtansine t-dm1 (100) 100
neoplasm metastasis (98) 98
neoplasms - drug therapy (98) 98
receptor (97) 97
medicine, research & experimental (96) 96
medical research (94) 94
antineoplastic agents - adverse effects (93) 93
brentuximab vedotin (93) 93
trastuzumab - administration & dosage (93) 93
safety (91) 91
article (90) 90
medical prognosis (89) 89
lapatinib plus capecitabine (88) 88
adjuvant trastuzumab (87) 87
trial (87) 87
breast neoplasms - mortality (86) 86
antibodies, monoclonal, humanized - adverse effects (85) 85
biopharmaceutics (84) 84
antineoplastic agents - administration & dosage (83) 83
toxicity (82) 82
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1518) 1518
French (14) 14
German (10) 10
Chinese (2) 2
Japanese (2) 2
Czech (1) 1
Spanish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England Journal of Medicine, ISSN 0028-4793, 11/2012, Volume 367, Issue 19, pp. 1783 - 1791
Women with metastatic breast cancer that had progressed during treatment with trastuzumab plus a taxane were assigned to lapatinib plus capecitabine or to... 
CAPECITABINE | LAPATINIB | MEDICINE, GENERAL & INTERNAL | THERAPY | PHASE-II | ANTIBODY | RECEPTOR | PLUS | Capecitabine | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Antineoplastic Agents - therapeutic use | Young Adult | Fluorouracil - administration & dosage | Neoplasm Metastasis - drug therapy | Antineoplastic Agents - adverse effects | Aged, 80 and over | Adult | Female | Quinazolines - administration & dosage | Antibodies, Monoclonal, Humanized - adverse effects | Maytansine - adverse effects | Antibodies, Monoclonal, Humanized - therapeutic use | Fluorouracil - analogs & derivatives | Maytansine - analogs & derivatives | Deoxycytidine - administration & dosage | Kaplan-Meier Estimate | Survival Rate | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Breast Neoplasms - pathology | Intention to Treat Analysis | Breast Neoplasms - mortality | Aged | Receptor, ErbB-2 - analysis | Deoxycytidine - analogs & derivatives | Trastuzumab | Drugs | Dose-response relationship (Biochemistry) | Breast cancer | Product/Service Evaluations | Drug therapy, Combination | Drug therapy | Comparative analysis | Thrombocytopenia | Chemotherapy | Epidermal growth factor | Vomiting | Diarrhea | Cytotoxicity | Nausea | Survival | ErbB-2 protein | Ovarian cancer | Index Medicus | Abridged Index Medicus
Journal Article
Journal Article
Cancer Chemotherapy and Pharmacology, ISSN 0344-5704, 5/2012, Volume 69, Issue 5, pp. 1229 - 1240
Trastuzumab emtansine (T-DM1) is an antibody–drug conjugate comprising trastuzumab and DM1, a microtubule polymerization inhibitor, covalently bound via a... 
Trastuzumab emtansine | Medicine & Public Health | Cancer Research | Oncology | Antibody–drug conjugate | T-DM1 | Breast cancer | Pharmacology/Toxicology | HER2 | Antibody-drug conjugate | BREAST-CANCER | ONCOLOGY | PHARMACOLOGY & PHARMACY | MBC | Antibodies, Monoclonal, Humanized - therapeutic use | Enzyme-Linked Immunosorbent Assay | Maytansine - analogs & derivatives | Humans | Middle Aged | Receptor, ErbB-2 - metabolism | Treatment Outcome | Maytansine - therapeutic use | Breast Neoplasms - drug therapy | Maytansine - pharmacology | Tandem Mass Spectrometry | Antibodies, Monoclonal, Humanized - pharmacokinetics | Breast Neoplasms - pathology | Antibodies, Monoclonal, Humanized - pharmacology | Maytansine - pharmacokinetics | Aged, 80 and over | Chromatography, Liquid | Adult | Female | Aged | Trastuzumab | Care and treatment | Oncology, Experimental | Antibodies | Polymerization | Liquid chromatography | Metastasis | Research | Antineoplastic agents | Chromatography | Viral antibodies | Antimitotic agents | Epidermal growth factor | Drug therapy | Mass spectrometry | Cancer | Index Medicus | Thrombocytopenia | Epidermal growth factor receptors | Liver | Data processing | Mass spectroscopy | Pharmacology | transaminase | ErbB-2 protein | trastuzumab | Immunogenicity | Microtubules | thioethers | Pharmacokinetics | Platelets | Enzyme-linked immunosorbent assay | Toxicology | Original
Journal Article
Journal Article
International Journal of Cancer, ISSN 0020-7136, 11/2016, Volume 139, Issue 10, pp. 2336 - 2342
Journal Article
Cancer Science, ISSN 1347-9032, 10/2018, Volume 109, Issue 10, pp. 3305 - 3315
Journal Article
Annals of Hepatology, ISSN 1665-2681, 10/2018, Volume 17, Issue 6, pp. 1067 - 1071
Trastuzumab is a monoclonal antibody targeted against the Human Epidermal Growth Factor Receptor 2 (HER2) overexpressed in some breast cancer. This targeted... 
Drug-induced disease | Nodular regenerative hyperplasia | Trastuzumab emtansine | Antibody-drug conjugate | SURVIVAL | SAFETY | ANTIBODY | SINUSOIDAL OBSTRUCTION | CHEMOTHERAPY | WOMEN | METASTATIC BREAST-CANCER | LIVER | GASTROENTEROLOGY & HEPATOLOGY
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 12/2012, Volume 118, Issue 23, pp. 5733 - 5740
Journal Article